Pharvaris (PHVS) Income towards Parent Company (2020 - 2026)
Pharvaris' (PHVS) quarterly Income towards Parent Company came in at -$45.8 million in Q1 2026, up 6.35% YoY from -$43.0 million in Q1 2025, and up 15.14% on a QoQ basis from -$53.9 million in Q4 2025.
Analysis
Pharvaris (PHVS) Income towards Parent Company (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Income towards Parent Company data on file, last reported at -$45.8 million in Q1 2026.
- Quarterly Income towards Parent Company rose 6.35% year-over-year to -$45.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$91.4 million (up 8.54% YoY) and the FY2025 annual result came in at -$198.5 million, down 36.64% from the prior year.
- Income towards Parent Company rose to -$45.8 million in Q1 2026, from -$53.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $51.8 million in Q2 2025 to a low of -$53.9 million in Q4 2025.
- A 5-year average of -$19.8 million and a median of -$30.4 million in 2024 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company surged 174.08% — and 2023, when it tumbled 207.77%.
- Tracing PHVS's Income towards Parent Company over 5 years: stood at -$40.1 million in 2022, then rose by 12.26% to -$35.2 million in 2023, then retreated by 5.39% to -$37.1 million in 2024, then slumped by 45.4% to -$53.9 million in 2025, then climbed by 15.14% to -$45.8 million in 2026.
- The last three Income towards Parent Company figures came in at -$45.8 million (Q1 2026), -$53.9 million (Q4 2025), and -$43.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Pharvaris | 2.14 Bn | 1.77 Bn | 85,072.10 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 54.87 Mn |
| Mar 31, 2026 | -45.78 Mn |
| Dec 31, 2025 | -54.42 Mn |
| Sep 30, 2025 | -43.43 Mn |
| Jun 30, 2025 | 51.78 Mn |
| Mar 31, 2025 | -48.88 Mn |
| Dec 31, 2024 | -36.94 Mn |
| Sep 30, 2024 | -45.92 Mn |
| Jun 30, 2024 | 31.99 Mn |
| Mar 31, 2024 | -30.40 Mn |
| Dec 31, 2023 | -35.26 Mn |
| Sep 30, 2023 | -25.69 Mn |
| Jun 30, 2023 | 23,843.36 Bn |
| Mar 31, 2023 | -24.32 Mn |
| Dec 31, 2022 | -40.10 Mn |
| Sep 30, 2022 | -8.35 Mn |
| Jun 30, 2022 | 13,562.46 Bn |
| Mar 31, 2022 | -17.98 Mn |
| Dec 31, 2021 | -14.09 Mn |
| Sep 30, 2021 | -10.78 Mn |